Federica Morano
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (15)
Kaplan Meier estimates of progression-free survival in the pMMR population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b).Legend: HR: hazard ratio, NR: not reached. Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOXIRI plus bevacizumab and atezolizumab.
Year:
2025
Forest plot depicting subgroup analyses for the efficacy of trastuzumab plus pertuzumab over trastuzumab plus placebo in terms of PFS (A), OS (B) and ORR (C) according to HER2 CNV (high vs low), HER2 IHC (3+ vs 2+) and AMNESIA status (positive vs negative).
Year:
2025
Kaplan Meier estimates of progression-free survival in the overall population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b).Legend: HR: hazard ratio, NR: not reached. Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOXIRI plus bevacizumab and atezolizumab.
Year:
2025
Supplementary Methods 1. Supplementary Methods, DNA extraction and whole exome sequencing, Mutation calling and mutational signatures, Whole transcriptome sequencing, Spatial profiling, Methods of A5 Discovery and Validation, Other statistical methods and reproducibility.
Year:
2025
Purpose: Peritoneal metastases (PM) in colorectal cancer portend a poor prognosis. We sought to elucidate molecular features differentiating primary tumors (PT) from PMs and actionable targets facilitating transcoelomic dissemination and progression. Experimental Design: We performed multiomic profiling of 227 samples from 136 patients, including 56 PTs and 120 synchronous PMs comprising 34 matched PT–PM pairs. Whole-exome and bulk RNA sequencing analyses were conducted to identify underlying genomic aberrations and transcriptomic differences between primary and peritoneal lesions. We spatially characterized the microenvironment of tumor–stroma compartments and studied the roles of stromal phenotypes in promulgating tumorigenesis. Results: Whole-exome sequencing found that genomic alterations and clonality patterns between PTs and PMs remain broadly similar. Transcriptomic profiles, however, suggest a transition as tumors reach the peritoneum toward a more mesenchymal tumor profile and fibrotic tumor microenvironment. Applying spatial profiling, we identify a fibro-collagenous and immune-infiltrated stromal phenotype [stromal cluster (SC) 2] characterized by increased cancer-associated fibroblasts, memory B cells, M2 macrophages, and T-cell exhaustion. These findings were orthogonally validated by multiplex IHC. Patients with SC2 stroma had poorer survival and were characterized by high SERPINE-1 ( PAI-1 ) expression. PMs in patients with SC2 stroma were associated with enriched oncogenic pathways such as TGF-β. PAI-1 inhibition of colorectal cancer PM cell lines with a novel biologic demonstrated reduced IL2–STAT5 and TGF-β pathways and cell death. Conclusions: Our findings unveil distinctive and actionable molecular signatures, offering deeper insights into the intricate cross-talk between tumor cells and stromal microenvironments enabling PM in colorectal cancer.
Year:
2025
Purpose: Novel combinations are required to overcome resistance to immune checkpoint inhibitors in proficient mismatch repair (pMMR) or microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). We aimed to determine whether vorbipiprant, a prostaglandin E2 receptor EP4 subtype antagonist, can convert immune-resistant mCRC into a tumor responsive to anti–PD-1 inhibition. Patients and Methods: This phase Ib/IIa prospective, open-label, single-arm trial followed a 3 + 3 dose-escalation and dose-optimization design. A total of 28 patients with chemorefractory pMMR/MSS mCRC were given dose-escalated oral vorbipiprant (30, 90, or 180 mg twice daily), along with biweekly intravenous balstilimab (3 mg/kg), an anti–PD-1 antibody. The primary endpoints included safety and the disease control rate (DCR). Secondary endpoints were the overall response rate, duration of response, progression-free survival, and overall survival. Results: No dose-limiting toxicities were observed. Of the 28 patients, seven (25%) experienced serious adverse events, but only one was attributed to vorbipiprant and one to balstilimab. The trial achieved a DCR of 50% observed across the entire cohort. In the subgroup of patients with liver metastases ( n = 12), the DCR was 25%. The overall response rate was 11%, with three patients showing a partial response (median duration of response, 7.4 months). The median progression-free survival was 2.6 months, and the median overall survival was 14.2 months. Translational exploratory analyses suggested that vorbipiprant may boost response to anti–PD-1 in patients with immunogenic tumors. Conclusions: The combination of vorbipiprant and a PD-1 inhibitor (balstilimab) yielded sufficient activity in refractory pMMR/MSS mCRC, which is worthy of confirmation in future clinical trials in biomarker-enriched populations.
Year:
2025
Trial profile and clinical response. Trial profile showing the number of patients screened, the patients enrolled, and, finally, the number of patients discontinued by the treatment groups ( A ). Swimmer plot showing the duration of treatment with vorbipiprant and balstilimab and RECIST overall tumor assessments ( B ). LM, liver metastases; PD, progressive disease. Spider plot showing the tumor burden over time presented as percentage change in the sum of the target lesions ( C ). Waterfall plot reporting treatment response according to PD-L1 CPS ( D ). NA, not assessable. Vorbipiprant dose always combined with the PD-1 inhibitor balstilimab, if not indicated.
Year:
2025
Gene expression signatures, immune cell enrichment and gene expression–based CMS, and association with treatment response. Treeplot depicting the results of hierarchical clustering of enriched terms from GSEA, comparing enriched pathways in patients with PFS 4 months ( A ). Bar plot reporting the results of the Student t test t statistics comparing inflammatory gene expression signature enrichment scores in patients with PFS >4 months vs. those with PFS B ). Heatmap of normalized enrichment scores of immune cell subtypes, comparing patients with PFS 4 months ( C ). DC, dendritic cells; iDC, immature dendritic cells; mDC, mature dendritic cells; MDSC, myeloid-derived suppressor cells; pDC, plasmacytoid dendritic cells; TFG, follicular helper T cells; TGD, gamma-delta T cells; Treg, regulatory T cells. Stacked barplots representing the proportion of patients assigned to gene expression CMS in patients with PFS >4 months ( n = 6) and patients with PFS n = 17; D ).
Year:
2025
Purpose: AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of patients with metastatic colorectal cancer (mCRC), with a modest benefit among proficient mismatch repair (pMMR). DetermaIO is an immune-related 27-gene expression signature able to predict benefit from immune checkpoint inhibition in triple-negative breast cancer. In this analysis of AtezoTRIBE, we investigated the predictive impact of DetermaIO in mCRC. Experimental Design: Patients with mCRC unselected for MMR status were randomly assigned (1:2) to FOLFOXIRI plus bevacizumab (control arm) or the same regimen with atezolizumab (atezolizumab arm). qRT-PCR by DetermaIO was performed on RNA purified from pretreatment tumors of 132 (61%) of 218 enrolled patients. A binary result (IO pos vs. IO neg ) adopting the preestablished DetermaIO cut-off point (0.09) was obtained, and an exploratory optimized cut-off point (IO OPT ) was computed in the overall population and in pMMR subgroup (IO OPTpos vs. IO OPTneg ). Results: DetermaIO was successfully determined in 122 (92%) cases, and 23 (27%) tumors were IO pos . IO pos tumors achieved higher PFS benefit from atezolizumab arm than IO neg (HR: 0.39 vs. 0.83; P interaction = 0.066). In pMMR tumors ( N = 110), a similar trend was observed (HR: 0.47 vs. 0.93; P interaction = 0.139). In the overall population, with the computed IO OPT cut-off point (0.277), 16 (13%) tumors were IO OPTpos and they derived higher PFS benefit from atezolizumab than IO OPTneg (HR: 0.10 vs. 0.85, P interaction = 0.004). Similar results were found in the pMMR subgroup. Conclusions: DetermaIO may be useful to predict benefit of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in mCRC. The exploratory IO OPT cut-off point should be validated in independent mCRC cohorts.
Year:
2025
Purpose: In JACOB trial, pertuzumab added to trastuzumab-chemotherapy did not significantly improve survival of patients with HER2-positive metastatic gastric cancer, despite 3.3 months increase versus placebo. HER2 copy-number variation (CNV) and AMNESIA panel encompassing primary resistance alterations ( KRAS/PIK3CA/MET mutations, KRAS/EGFR/MET amplifications) may improve patients’ selection for HER2 inhibition. Experimental Design: In a post hoc analysis of JACOB on 327 samples successfully sequenced by next-generation sequencing (NGS; Oncomine Focus DNA), HER2 CNV, HER2 expression by IHC, and AMNESIA were correlated with overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) by univariable/multivariable models. Results: Median HER2 CNV was 4.7 (interquartile range, 2.2–16.9). HER2 CNV-high versus low using the median as cutoff was associated with longer median PFS (10.5 vs. 6.4 months; HR = 0.48; 95% confidence interval: 0.38–0.62; P P HER2 CNV and IHC improved discriminative ability, with better outcomes restricted to HER2 -high/HER2 3+ subgroup. AMNESIA positivity was found in 51 (16%), with unadjusted HR = 1.35 (0.98–1.86) for PFS; 1.43 (1.00–2.03) for OS. In multivariable models, only HER2 CNV status remained significant for PFS ( P P = 0.004). Higher ORR was significantly associated with IHC 3+ [61% vs. 34% in 2+; OR = 3.11 (1.89–5.17)] and HER2 -high [59% vs. 43% in HER2 -low; OR = 1.84 (1.16–2.94)], with highest OR in the top CNV quartile. These biomarkers were not associated with treatment effect of pertuzumab. Conclusions: HER2 CNV-high assessed by NGS may be associated with better ORR, PFS, and OS in a JACOB subgroup, especially if combined with HER2 3+. The negative prognostic role of AMNESIA requires further clinical validation.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (27)
Samuel Klempner
Associate Professor
Massachusetts General Hospital
Joseph J Zhao
National University of Singapore
Jérôme Galon
Research Director
INSERM
Raghav Sundar
Associate Professor
Yale University
Lucio Rovati
Chief, Executive Officer
-
Haoran Ma
National University of Singapore
Filippo Pietrantonio
Researcher (non-academic)
Fondazione IRCCS Istituto Nazionale dei Tumori
Lorenzo Castagnoli
Open University
Lit-Hsin Loo
Senior Principal Investigator
ImmunoQs Pte Ltd
Enrico Berrino
Università degli Studi di Foggia Dipartimento di Scienze Mediche e Chirurgiche
Josep Tabernero
Associate Professor Faculty of Medicine
Universitat de Vic - Universitat Central de Catalunya
Caterina MARCHIO'
Associate Professor of Pathology
University of Turin
Serenella Pupa
Fondazione IRCCS Istituto Nazionale dei Tumori
sara erika bellomo
Candiolo Cancer Institute, FPO-IRCCS
Paolo Manca
Research Scholar
Fondazione IRCCS Istituto Nazionale dei Tumori
Valentina Doldi
Fondazione IRCCS Istituto Nazionale dei Tumori
Jolene Wong
Clinical Assistant Professor & Consultant
Singapore General Hospital
Supriya Srivastava
Senior Research Fellow
National University Singapore Yong Loo Lin School of Medicine
Silvia GIORDANO
full professor
University of Turin
Cristina Migliore
Candiolo Cancer Institute, FPO-IRCCS
Simona CORSO
Associate Professor
Candiolo Cancer Institute, FPO-IRCCS
Maarten F. Bijlsma
Staff scientist
Academic Medical Center
Monica Niger
Fondazione IRCCS Istituto Nazionale dei Tumori
Claudia Chiodoni
Senior Staff scientist
Fondazione IRCCS Istituto Nazionale dei Tumori
Chiara Cremolini
University Hospital of Pisa
Nadia Zaffaroni
Head of Research Unit (Molecular Pharmacology)
Fondazione IRCCS Istituto Nazionale dei Tumori
Louis Vermeulen
Group leader / PI
-
Make your next move.
Prepare your application
Review drafts before you send them.